Does aspirin prevent cancer?
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Aspirin and Cancer Prevention: An Overview
Aspirin and Colorectal Cancer Prevention
Evidence from USPSTF Recommendations
The U.S. Preventive Services Task Force (USPSTF) has recommended the use of low-dose aspirin for the primary prevention of colorectal cancer (CRC) in specific populations. Adults aged 50 to 59 years with a 10% or greater 10-year cardiovascular disease (CVD) risk, who are not at increased risk for bleeding, and have a life expectancy of at least 10 years, may benefit from daily low-dose aspirin use for at least 10 years. For adults aged 60 to 69 years, the decision to use aspirin should be individualized, considering the potential benefits and harms.
Systematic Reviews and Meta-Analyses
Several systematic reviews and meta-analyses have explored the relationship between aspirin use and cancer prevention. One umbrella review found that while aspirin may have potential preventive effects on certain cancers, including colorectal cancer, the evidence is not uniformly strong across all cancer types. Another meta-analysis concluded that aspirin use did not significantly reduce cancer-related mortality or incidence but was associated with higher rates of bleeding .
Aspirin and General Cancer Prevention
Total Cancer Incidence and Mortality
Research has shown mixed results regarding aspirin's effectiveness in reducing overall cancer incidence and mortality. A comprehensive review for the USPSTF found no established groups recommending aspirin for general cancer prevention, except for individuals at high risk for CRC, such as those with Lynch syndrome. Additionally, a meta-analysis of randomized controlled trials (RCTs) indicated that aspirin did not significantly reduce cancer-related mortality or overall cancer incidence compared to placebo .
Long-Term Effects and Specific Cancers
Long-term studies have suggested that daily aspirin use for five years or longer may reduce the risk of death from several common cancers, particularly gastrointestinal cancers. The benefit appears to increase with the duration of aspirin use and is consistent across different study populations. However, the evidence supporting aspirin's preventive role in cancers such as breast, non-cardia gastric, and prostate cancer remains weak or not suggestive.
Safety Concerns and Adherence
Risks of Bleeding
One of the significant concerns with long-term aspirin use is the increased risk of bleeding. Studies have consistently shown that aspirin use is associated with higher rates of any bleeding, major bleeding, and gastrointestinal bleeding compared to placebo . This risk necessitates careful consideration of the benefits and harms before initiating aspirin for cancer prevention.
Patient and Healthcare Provider Attitudes
Despite clinical guidelines recommending aspirin for cancer prevention, uptake and adherence remain low. Most patients offered aspirin for cancer prevention do not initiate therapy, although those who do tend to adhere well in the short term. Healthcare providers also show low rates of recommending aspirin for cancer prevention in clinical practice.
Conclusion
The role of aspirin in cancer prevention, particularly colorectal cancer, is supported by some evidence, especially for specific high-risk populations. However, the general use of aspirin for cancer prevention remains controversial due to mixed evidence on its efficacy and significant safety concerns related to bleeding. Individualized decision-making, considering the potential benefits and risks, is crucial for those considering aspirin for cancer prevention.
Sources and full results
Most relevant research papers on this topic